Annual CFO
-$260.38 M
+$235.37 M+47.48%
31 December 2023
Summary:
CRISPR Therapeutics AG annual cash flow from operations is currently -$260.38 million, with the most recent change of +$235.37 million (+47.48%) on 31 December 2023. During the last 3 years, it has fallen by -$22.01 million (-9.23%). CRSP annual CFO is now -148.31% below its all-time high of $538.97 million, reached on 31 December 2021.CRSP Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$106.91 M
-$11.33 M-11.85%
30 September 2024
Summary:
CRISPR Therapeutics AG quarterly cash flow from operations is currently -$106.91 million, with the most recent change of -$11.33 million (-11.85%) on 30 September 2024. Over the past year, it has dropped by -$67.06 million (-168.25%). CRSP quarterly CFO is now -113.25% below its all-time high of $807.00 million, reached on 30 June 2021.CRSP Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$188.82 M
-$67.06 M-55.07%
30 September 2024
Summary:
CRISPR Therapeutics AG TTM cash flow from operations is currently -$188.82 million, with the most recent change of -$67.06 million (-55.07%) on 30 September 2024. Over the past year, it has increased by +$88.81 million (+31.99%). CRSP TTM CFO is now -134.37% below its all-time high of $549.43 million, reached on 30 June 2021.CRSP TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CRSP Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +47.5% | -168.3% | +32.0% |
| 3 y3 years | -9.2% | -31.5% | -134.7% |
| 5 y5 years | -170.6% | -180.1% | -857.4% |
CRSP Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -148.3% | +47.5% | -197.4% | +24.7% | -134.7% | +61.9% |
| 5 y | 5 years | -148.3% | +47.5% | -113.3% | +24.7% | -134.4% | +61.9% |
| alltime | all time | -148.3% | +47.5% | -113.3% | +24.7% | -134.4% | +61.9% |
CRISPR Therapeutics AG Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$106.91 M(+11.9%) | -$188.82 M(+55.1%) |
| June 2024 | - | -$95.58 M(-187.1%) | -$121.76 M(-23.6%) |
| Mar 2024 | - | $109.75 M(-214.2%) | -$159.42 M(-38.8%) |
| Dec 2023 | -$260.38 M(-47.5%) | -$96.07 M(+141.1%) | -$260.38 M(-6.2%) |
| Sept 2023 | - | -$39.86 M(-70.1%) | -$277.63 M(-19.1%) |
| June 2023 | - | -$133.25 M(-1614.3%) | -$342.99 M(-2.5%) |
| Mar 2023 | - | $8.80 M(-107.8%) | -$351.70 M(-29.1%) |
| Dec 2022 | -$495.74 M(-192.0%) | -$113.33 M(+7.7%) | -$495.74 M(+5.8%) |
| Sept 2022 | - | -$105.22 M(-25.9%) | -$468.45 M(+5.4%) |
| June 2022 | - | -$141.96 M(+5.0%) | -$444.56 M(-188.1%) |
| Mar 2022 | - | -$135.24 M(+57.2%) | $504.40 M(-6.4%) |
| Dec 2021 | $538.97 M(-326.1%) | -$86.04 M(+5.8%) | $538.97 M(-0.9%) |
| Sept 2021 | - | -$81.33 M(-110.1%) | $543.80 M(-1.0%) |
| June 2021 | - | $807.00 M(-901.7%) | $549.43 M(-291.5%) |
| Mar 2021 | - | -$100.66 M(+24.0%) | -$286.85 M(+20.3%) |
| Dec 2020 | -$238.37 M | -$81.21 M(+7.3%) | -$238.37 M(+55.0%) |
| Sept 2020 | - | -$75.70 M(+158.5%) | -$153.78 M(-377.9%) |
| June 2020 | - | -$29.28 M(-43.9%) | $55.34 M(+14.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | -$52.17 M(-1645.5%) | $48.24 M(-14.9%) |
| Dec 2019 | $56.68 M(-158.9%) | $3.38 M(-97.5%) | $56.68 M(+127.4%) |
| Sept 2019 | - | $133.42 M(-466.7%) | $24.93 M(-119.4%) |
| June 2019 | - | -$36.38 M(-16.8%) | -$128.46 M(+9.5%) |
| Mar 2019 | - | -$43.74 M(+54.2%) | -$117.29 M(+21.9%) |
| Dec 2018 | -$96.24 M(+37.3%) | -$28.37 M(+42.1%) | -$96.24 M(+16.4%) |
| Sept 2018 | - | -$19.96 M(-20.8%) | -$82.71 M(+5.2%) |
| June 2018 | - | -$25.21 M(+11.1%) | -$78.61 M(+13.3%) |
| Mar 2018 | - | -$22.69 M(+52.9%) | -$69.37 M(-1.0%) |
| Dec 2017 | -$70.09 M(+32.6%) | -$14.84 M(-6.5%) | -$70.09 M(-2.9%) |
| Sept 2017 | - | -$15.87 M(-0.7%) | -$72.22 M(+5.2%) |
| June 2017 | - | -$15.97 M(-31.8%) | -$68.63 M(+3.6%) |
| Mar 2017 | - | -$23.41 M(+38.0%) | -$66.26 M(+25.3%) |
| Dec 2016 | -$52.86 M(-188.9%) | -$16.97 M(+38.2%) | -$52.86 M(+47.3%) |
| Sept 2016 | - | -$12.28 M(-9.8%) | -$35.89 M(+52.0%) |
| June 2016 | - | -$13.60 M(+35.8%) | -$23.62 M(+135.8%) |
| Mar 2016 | - | -$10.01 M | -$10.01 M |
| Dec 2015 | $59.43 M(-1339.9%) | - | - |
| Dec 2014 | -$4.79 M | - | - |
FAQ
- What is CRISPR Therapeutics AG annual cash flow from operations?
- What is the all time high annual CFO for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG annual CFO year-on-year change?
- What is CRISPR Therapeutics AG quarterly cash flow from operations?
- What is the all time high quarterly CFO for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG quarterly CFO year-on-year change?
- What is CRISPR Therapeutics AG TTM cash flow from operations?
- What is the all time high TTM CFO for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG TTM CFO year-on-year change?
What is CRISPR Therapeutics AG annual cash flow from operations?
The current annual CFO of CRSP is -$260.38 M
What is the all time high annual CFO for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high annual cash flow from operations is $538.97 M
What is CRISPR Therapeutics AG annual CFO year-on-year change?
Over the past year, CRSP annual cash flow from operations has changed by +$235.37 M (+47.48%)
What is CRISPR Therapeutics AG quarterly cash flow from operations?
The current quarterly CFO of CRSP is -$106.91 M
What is the all time high quarterly CFO for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high quarterly cash flow from operations is $807.00 M
What is CRISPR Therapeutics AG quarterly CFO year-on-year change?
Over the past year, CRSP quarterly cash flow from operations has changed by -$67.06 M (-168.25%)
What is CRISPR Therapeutics AG TTM cash flow from operations?
The current TTM CFO of CRSP is -$188.82 M
What is the all time high TTM CFO for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high TTM cash flow from operations is $549.43 M
What is CRISPR Therapeutics AG TTM CFO year-on-year change?
Over the past year, CRSP TTM cash flow from operations has changed by +$88.81 M (+31.99%)